In vitro Activity of SCH-34343, a New Penam, and Other Antimicrobial Agents against Clinical Isolates from Cancer Patients

Abstract

The in vitro activity of SCH-34343, a new penam antibiotic, was tested against gram-positive and gram-negative isolates from cancer patients, and compared to that of 7 other antimicrobial agents. SCH-34343 was extremely active against the Enterobacteriaceae with MIC₉₀s ranging from 0.39 to 6.25 μg/ml for Citrobacter spp., Enterobacter spp., Escherichia coli, Klebsiella spp., Proteus spp. and Serratia marcescens. It was less active against Acinetobacter spp. (MIC₉₀ 6.25–12.5 μg/ml) and had poor activity against Pseudomonas aeruginosa. Among gram-positive isolates group A and G β-hemolytic Streptococci were extremely susceptible to SCH-34343 (MIC₉₀ 0.025–0.05 μg/ml). Good activity against methicillin-susceptible coagulase-positive and coagulase-negative Staphylococci and Listeria monocytogenes, and moderate activity against Enterococci was also seen.

In vitro Activity of Fleroxacin (Ro23-6240), a New Fluorinated 4-Quinolone against Isolates from Cancer Patients

“…Antimicrobial susceptibility testing was per formed using a previously described microtiter broth dilution method [7]. Briefly, Mueller-Hinton broth was used as the test medium for all organisms except group A and group G streptococci for which tryptase phosphate broth was used, and for CDC-J K diphthe roids for which brain heart infusion broth with 5% rabbit serum was used.…”